Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplas...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2000-01, Vol.79 (1), p.30-35 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 30 |
| container_title | Annals of hematology |
| container_volume | 79 |
| creator | GANSER, A HEIL, G FUHR, H. G KNUTH, P HÖFFKEN, K BERGMANN, L HOELZER, D SEIPELT, G HOFMANN, W FISCHER, J. T LANGER, W BROCKHAUS, W KOLBE, K ITTEL, H BRACK, N |
| description | Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged 60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged |
| doi_str_mv | 10.1007/s002770050005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70903162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70903162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-18ddcc79966a9c782c04cf739c52f1b7b71cabbe5d9143dfdd7201ed7b7f32143</originalsourceid><addsrcrecordid>eNp90VFr1TAUB_AgirtOH32VgCITVj1J2qZ9LJepg3vxQX0uaZLabE3SJa2jX22fzsx7Qd2DgRA4-fE_JAehlwTeEwD-IQJQzgEKSPsR2pCc0QyKKn-MNlCzOivSOkHPYrwCILTK6VN0QqAsWUmqDbq7dLN20fzUWA7a-nnQQUwrvjXzgI0SYemMNO4ciyCy7TnWs598NEqnilPYZs3-a4N7P47-VivcrdhYu7gHOalHGPVybVxGEw7Yrnr0ao3TKOJsJI6rU8FbHX-nDubHkAUTr3Ejl1nj_b02Cu9ShLZG4LNmv3v3HD3pxRj1i-N5ir5_vPi2_Zztvny63Da7TDJezxmplJKS13VZilryikrIZc9ZLQvak453nEjRdbpQdfo71SvFKRCt0kXPaCqdoreH3Cn4m0XHubUmSj2Owmm_xJZDDYyUNMGz_0LCSFFCSYEn-voBvfJLcOkZLQFSME4ZQFLZQcngYwy6b6dgrAhrQu399Nt_pp_8q2Pq0lmt_tKHcSfw5ghElGLsg3DSxD-O5pBzwn4BDP-4cA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015372300</pqid></control><display><type>article</type><title>Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>GANSER, A ; HEIL, G ; FUHR, H. G ; KNUTH, P ; HÖFFKEN, K ; BERGMANN, L ; HOELZER, D ; SEIPELT, G ; HOFMANN, W ; FISCHER, J. T ; LANGER, W ; BROCKHAUS, W ; KOLBE, K ; ITTEL, H ; BRACK, N</creator><creatorcontrib>GANSER, A ; HEIL, G ; FUHR, H. G ; KNUTH, P ; HÖFFKEN, K ; BERGMANN, L ; HOELZER, D ; SEIPELT, G ; HOFMANN, W ; FISCHER, J. T ; LANGER, W ; BROCKHAUS, W ; KOLBE, K ; ITTEL, H ; BRACK, N</creatorcontrib><description>Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged </=60 years and 35% aged >60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged </=60 years than among the older patients (16 vs 6 months, p<0.001). Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s002770050005</identifier><identifier>PMID: 10663618</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Acute Disease ; Acute myeloid leukemia ; Adolescent ; Adult ; Age ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Blast ; Bone marrow transplantation ; Chemotherapy ; Clinical trials ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Cytarabine - administration & dosage ; Donors ; Dose-Response Relationship, Drug ; Etoposide ; Etoposide - administration & dosage ; Female ; Histocompatibility antigen HLA ; Humans ; Idarubicin - administration & dosage ; Immunotherapy ; Interleukin 2 ; Interleukin-2 - therapeutic use ; Leukemia, Myeloid - drug therapy ; Male ; Medical sciences ; Middle Aged ; Myelodysplastic syndrome ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - drug therapy ; Myelodysplastic Syndromes - therapy ; Pharmacology. Drug treatments ; Prospective Studies ; Refractory anemia ; Remission ; Risk groups ; Siblings ; Survival ; Survival Rate ; Transformation</subject><ispartof>Annals of hematology, 2000-01, Vol.79 (1), p.30-35</ispartof><rights>2000 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-18ddcc79966a9c782c04cf739c52f1b7b71cabbe5d9143dfdd7201ed7b7f32143</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1240471$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10663618$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GANSER, A</creatorcontrib><creatorcontrib>HEIL, G</creatorcontrib><creatorcontrib>FUHR, H. G</creatorcontrib><creatorcontrib>KNUTH, P</creatorcontrib><creatorcontrib>HÖFFKEN, K</creatorcontrib><creatorcontrib>BERGMANN, L</creatorcontrib><creatorcontrib>HOELZER, D</creatorcontrib><creatorcontrib>SEIPELT, G</creatorcontrib><creatorcontrib>HOFMANN, W</creatorcontrib><creatorcontrib>FISCHER, J. T</creatorcontrib><creatorcontrib>LANGER, W</creatorcontrib><creatorcontrib>BROCKHAUS, W</creatorcontrib><creatorcontrib>KOLBE, K</creatorcontrib><creatorcontrib>ITTEL, H</creatorcontrib><creatorcontrib>BRACK, N</creatorcontrib><title>Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged </=60 years and 35% aged >60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged </=60 years than among the older patients (16 vs 6 months, p<0.001). Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms.</description><subject>Acute Disease</subject><subject>Acute myeloid leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blast</subject><subject>Bone marrow transplantation</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Cytarabine - administration & dosage</subject><subject>Donors</subject><subject>Dose-Response Relationship, Drug</subject><subject>Etoposide</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Idarubicin - administration & dosage</subject><subject>Immunotherapy</subject><subject>Interleukin 2</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Leukemia, Myeloid - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Refractory anemia</subject><subject>Remission</subject><subject>Risk groups</subject><subject>Siblings</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Transformation</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90VFr1TAUB_AgirtOH32VgCITVj1J2qZ9LJepg3vxQX0uaZLabE3SJa2jX22fzsx7Qd2DgRA4-fE_JAehlwTeEwD-IQJQzgEKSPsR2pCc0QyKKn-MNlCzOivSOkHPYrwCILTK6VN0QqAsWUmqDbq7dLN20fzUWA7a-nnQQUwrvjXzgI0SYemMNO4ciyCy7TnWs598NEqnilPYZs3-a4N7P47-VivcrdhYu7gHOalHGPVybVxGEw7Yrnr0ao3TKOJsJI6rU8FbHX-nDubHkAUTr3Ejl1nj_b02Cu9ShLZG4LNmv3v3HD3pxRj1i-N5ir5_vPi2_Zztvny63Da7TDJezxmplJKS13VZilryikrIZc9ZLQvak453nEjRdbpQdfo71SvFKRCt0kXPaCqdoreH3Cn4m0XHubUmSj2Owmm_xJZDDYyUNMGz_0LCSFFCSYEn-voBvfJLcOkZLQFSME4ZQFLZQcngYwy6b6dgrAhrQu399Nt_pp_8q2Pq0lmt_tKHcSfw5ghElGLsg3DSxD-O5pBzwn4BDP-4cA</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>GANSER, A</creator><creator>HEIL, G</creator><creator>FUHR, H. G</creator><creator>KNUTH, P</creator><creator>HÖFFKEN, K</creator><creator>BERGMANN, L</creator><creator>HOELZER, D</creator><creator>SEIPELT, G</creator><creator>HOFMANN, W</creator><creator>FISCHER, J. T</creator><creator>LANGER, W</creator><creator>BROCKHAUS, W</creator><creator>KOLBE, K</creator><creator>ITTEL, H</creator><creator>BRACK, N</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20000101</creationdate><title>Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)</title><author>GANSER, A ; HEIL, G ; FUHR, H. G ; KNUTH, P ; HÖFFKEN, K ; BERGMANN, L ; HOELZER, D ; SEIPELT, G ; HOFMANN, W ; FISCHER, J. T ; LANGER, W ; BROCKHAUS, W ; KOLBE, K ; ITTEL, H ; BRACK, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-18ddcc79966a9c782c04cf739c52f1b7b71cabbe5d9143dfdd7201ed7b7f32143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Acute Disease</topic><topic>Acute myeloid leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blast</topic><topic>Bone marrow transplantation</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Cytarabine - administration & dosage</topic><topic>Donors</topic><topic>Dose-Response Relationship, Drug</topic><topic>Etoposide</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Idarubicin - administration & dosage</topic><topic>Immunotherapy</topic><topic>Interleukin 2</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Leukemia, Myeloid - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Refractory anemia</topic><topic>Remission</topic><topic>Risk groups</topic><topic>Siblings</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Transformation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GANSER, A</creatorcontrib><creatorcontrib>HEIL, G</creatorcontrib><creatorcontrib>FUHR, H. G</creatorcontrib><creatorcontrib>KNUTH, P</creatorcontrib><creatorcontrib>HÖFFKEN, K</creatorcontrib><creatorcontrib>BERGMANN, L</creatorcontrib><creatorcontrib>HOELZER, D</creatorcontrib><creatorcontrib>SEIPELT, G</creatorcontrib><creatorcontrib>HOFMANN, W</creatorcontrib><creatorcontrib>FISCHER, J. T</creatorcontrib><creatorcontrib>LANGER, W</creatorcontrib><creatorcontrib>BROCKHAUS, W</creatorcontrib><creatorcontrib>KOLBE, K</creatorcontrib><creatorcontrib>ITTEL, H</creatorcontrib><creatorcontrib>BRACK, N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GANSER, A</au><au>HEIL, G</au><au>FUHR, H. G</au><au>KNUTH, P</au><au>HÖFFKEN, K</au><au>BERGMANN, L</au><au>HOELZER, D</au><au>SEIPELT, G</au><au>HOFMANN, W</au><au>FISCHER, J. T</au><au>LANGER, W</au><au>BROCKHAUS, W</au><au>KOLBE, K</au><au>ITTEL, H</au><au>BRACK, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>79</volume><issue>1</issue><spage>30</spage><epage>35</epage><pages>30-35</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged </=60 years and 35% aged >60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged </=60 years than among the older patients (16 vs 6 months, p<0.001). Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>10663618</pmid><doi>10.1007/s002770050005</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2000-01, Vol.79 (1), p.30-35 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70903162 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acute Disease Acute myeloid leukemia Adolescent Adult Age Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Blast Bone marrow transplantation Chemotherapy Clinical trials Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Cytarabine - administration & dosage Donors Dose-Response Relationship, Drug Etoposide Etoposide - administration & dosage Female Histocompatibility antigen HLA Humans Idarubicin - administration & dosage Immunotherapy Interleukin 2 Interleukin-2 - therapeutic use Leukemia, Myeloid - drug therapy Male Medical sciences Middle Aged Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - therapy Pharmacology. Drug treatments Prospective Studies Refractory anemia Remission Risk groups Siblings Survival Survival Rate Transformation |
| title | Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A48%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intensive%20chemotherapy%20with%20idarubicin,%20ara-C,%20etoposide,%20and%20m-AMSA%20followed%20by%20immunotherapy%20with%20interleukin-2%20for%20myelodysplastic%20syndromes%20and%20high-risk%20Acute%20Myeloid%20Leukemia%20(AML)&rft.jtitle=Annals%20of%20hematology&rft.au=GANSER,%20A&rft.date=2000-01-01&rft.volume=79&rft.issue=1&rft.spage=30&rft.epage=35&rft.pages=30-35&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s002770050005&rft_dat=%3Cproquest_cross%3E70903162%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015372300&rft_id=info:pmid/10663618&rfr_iscdi=true |